Profound Medical (PROF) Net Income towards Common Stockholders Growth (3y) (2022 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -2.19% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 64.73% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 30.89% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 60.12% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 29.56% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Profound Medical | 244.28 Mn | 193.99 Mn | 3.83 Mn | 2.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.01% |
| Dec 31, 2025 | 53.58% |
| Sep 30, 2025 | -53.37% |
| Jun 30, 2025 | -66.96% |
| Mar 31, 2025 | 9.43% |
| Dec 31, 2024 | 44.13% |
| Sep 30, 2024 | -52.91% |
| Jun 30, 2024 | -44.07% |
| Mar 31, 2024 | -42.30% |
| Sep 30, 2023 | -2.27% |
| Jun 30, 2023 | 12.18% |
| Mar 31, 2023 | 36.75% |
| Dec 31, 2022 | -72.66% |
| Sep 30, 2022 | 1.69% |
| Jun 30, 2022 | 10.76% |
| Mar 31, 2022 | 55.53% |